PMCB · PharmaCyte Biotech, Inc.
Substantial doubt about the company's ability to continue as a going concern.
“Any such required financing may not be available in amounts or on terms acceptable to us, and the failure to procure such required financing could have a material and adverse effect on our business, financial condition and results of operations, or threaten our ability to continue as a going concern.”View the 10-K filed Jul 29, 2026
Share-repurchase activity from the company's own XBRL filings — cash spent buying back common stock per fiscal year and per recent quarter, share counts where the company tagged them, and the buyback program's authorization — paired with the company's at-the-market (ATM) equity offering programs, the dilution side of the same picture. Repurchase amounts come exclusively from tagged SEC data; program figures with no tagged equivalent (untagged authorizations and all ATM figures) are read from the filing's own text and shown only after verification.
| Program Announced | Authorized | Remaining | As of | Runs Through | Source |
|---|---|---|---|---|---|
| 2023-01-31 | $10,000,000 | — | — | — | 10-K , filed 2026-07-29 |
Cash spent on buybacks by quarter
Cash deployed each quarter, with the average price paid where the company reported it. Δ marks quarters derived from the company's cumulative year-to-date disclosures.
Repurchase History
| Fiscal Year Ended | Cash Spent | Source |
|---|---|---|
| 2026-04-30 | $401,625 | 10-K, filed 2026-07-29 |
| 2025-04-30 | $2,542,276 | 10-K, filed 2026-07-29 |
| 2024-04-30 | $28,197,617 | 10-K, filed 2025-08-11 |
| 2023-04-30 | $13,560,623 | 10-K, filed 2024-08-13 |
| 2022-04-30 | $0 | 10-K, filed 2023-07-31 |